A Phase 1 interventional study of brentuximab vedotin and Brentuximab vedotin and rifampicin in Hodgkin Lymphoma and Anaplastic Large-cell Lymphoma, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 6 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-05-11.
Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 80 studies testing Brentuximab Vedotin in Hodgkin Disease — 14 open to participants now, 28 under way, 8 of them phase 3. Brentuximab Vedotin · Hodgkin Disease.
Among the 80 studies testing Brentuximab Vedotin in Hodgkin Disease, this one is the 66th largest by enrollment, is one of 10 that started in 2013, is one of 12 in phase 1, and was the 26th registered.
1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.
Browse Hodgkin Disease studies →14 of the 80 studies testing Brentuximab Vedotin in Hodgkin Disease are open now, in 12 countries. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
University of Miami · Sites in United States
Ages 18–60
Children's Cancer Group, China · Sites in China
Ages 2–35
Takeda · Sites in India
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Brentuximab Vedotin: first FDA approval 2011 (ADCETRIS), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 136 Hodgkin Disease studies recruiting now, 73 (54%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
80 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 56 · Phase 3 11 · Phase 4 2
First in 2006; this study’s year is marked. 10 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 40 across 1,095 interventional studies indexed under Hodgkin Disease.
Median enrollment 52 across the 80 interventional studies. Of the 46 that completed or were terminated, 26 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 80 have an industry lead sponsor. The 10 most frequent:
This study is registered under Millennium Pharmaceuticals, Inc., one of the names counted as Takeda. Under that name alone:
Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.
Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.
15 studies in Hodgkin Disease by Takeda: 3 open now, 4 under way, none of them phase 3. Of 10 finished, 6 (60%) have results posted.
Among the 15 studies in Hodgkin Disease by Takeda, this one is the only one that started in 2013, is one of 2 in phase 1, and was the 5th registered.
Takeda’s Hodgkin Disease studies by the year they started, since 1997.
7 of the studies testing Brentuximab Vedotin in Hodgkin Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05180097Canadian Cancer Trials GroupPembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma | 2026-12-31 |
| NCT03755804St. Jude Children's Research HospitalPediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 | 2027-01-01 |
| NCT06377566Memorial Sloan Kettering Cancer CenterA Study of BV-AVD in People With Bulky Hodgkin Lymphoma | 2027-04 |
| NCT04561206City of Hope Medical CenterBrentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma | 2027-10-02 |
| NCT05404945University of VirginiaFitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above | 2027-10-03 |
Add all 7 to your calendar (.ics) → With an account.
Among the 80 studies testing Brentuximab Vedotin in Hodgkin Disease, from their registry updates:
Among Takeda’s 15 in Hodgkin Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an open-label trial to estimate the concentrations of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma (HL) or relapsed/refractory systemic anaplastic large cell lymphoma (sALCL) participants treated with either brentuximab vedotin or brentuximab vedotin + rifampicin.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg.
Drug: brentuximab vedotin
Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg beginning on Cycle 1, Day 1; daily rifampicin (600 mg PO) will be administered during Cycles 0 through 3 only, beginning on Cycle 0, Day 1 (7 days before the Cycle 1, Day 1 dose of brentuximab vedotin) and continuing through Cycle 3, Day 21.
Drug: Brentuximab vedotin and rifampicin
Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg.
Also known as: SGN-35
Drug pages: Brentuximab Vedotin · Rifampin
Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg beginning on Cycle 1, Day 1; daily rifampicin (600 mg PO) will be administered during Cycles 0 through 3 only, beginning on Cycle 0, Day 1 (7 days before the Cycle 1, Day 1 dose of brentuximab vedotin) and continuing through Cycle 3, Day 21.
Also known as: SGN-35
Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, Predose
Metabolites of MMAE includes C4, C5, C7, C8 and C13. The lower limit of Quantification (LLQ) for all the observations was 0.01 nanogram/milliliter (ng/mL).
Time frame: Cycle 1: Predose
Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 2, Predose
Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.
Time frame: Cycle 2: Predose
Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, Predose
Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.
Time frame: Cycle 3: Predose
Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, 0.5 Hour Postdose
Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.
Time frame: Cycle 1: 0.5 hour postdose
Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 2, 0.5 Hour Postdose
Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.
Time frame: Cycle 2: 0.5 hour postdose
Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, 0.5 Hour Postdose
Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.
Time frame: Cycle 3: 0.5 hour postdose
Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, 4 Hour Postdose
Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.
Time frame: Cycle 1: 4 hour postdose
Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, 4 Hour Postdose
Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.
Time frame: Cycle 3: 4 hour postdose
Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, 24 Hour Postdose
Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.
Time frame: Cycle 1: 24 hour postdose
Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, 24 Hour Postdose
Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.
Time frame: Cycle 3: 24 hour postdose
Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, 48 Hour Postdose
Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.
Time frame: Cycle 1: 48 hour postdose
Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, 48 Hour Postdose
Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.
Time frame: Cycle 3: 48 hour postdose
Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, 72 Hour Postdose
Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.
Time frame: Cycle 1: 72 hour postdose
Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, 72 Hour Postdose
Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.
Time frame: Cycle 3: 72 hour postdose
Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, 96 Hour Postdose
Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.
Time frame: Cycle 1: 96 hour postdose
Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, 96 Hour Postdose
Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.
Time frame: Cycle 3: 96 hour postdose
Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, 144 Hour Postdose
Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.
Time frame: Cycle 1: 144 hour postdose
Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, 144 Hour Postdose
Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.
Time frame: Cycle 3: 144 hour postdose
Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, 336 Hour Postdose
Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.
Time frame: Cycle 1: 336 hour postdose
Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, 336 Hour Postdose
Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.
Time frame: Cycle 3: 336 hour postdose
Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, 480 Hour Postdose
Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.
Time frame: Cycle 3: 480 hour postdose
Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, Predose
Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.
Time frame: Cycle 1: Predose
Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, 0-24 Hours Postdose
Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.
Time frame: Cycle 1: 0-24 hours postdose
Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, 24-48 Hours Postdose
Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.
Time frame: Cycle 1: 24-48 hours postdose
Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, 48-72 Hours Postdose
Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.
Time frame: Cycle 1: 48-72 hours postdose
Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, 72-96 Hours Postdose
Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.
Time frame: Cycle 1: 72-96 hours postdose
Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, 96-120 Hours Postdose
Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.
Time frame: Cycle 1: 96-120 hours postdose
Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, 120-144 Hours Postdose
Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.
Time frame: Cycle 1: 120-144 hours postdose
Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, 144-168 Hours Postdose
Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.
Time frame: Cycle 1: 144-168 hours postdose
Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, 336-360 Hours Postdose
Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.
Time frame: Cycle 1: 336-360 hours postdose
Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, 480-504 Hours Postdose
Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.
Time frame: Cycle 1: 480-504 hours postdose
Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, Predose
Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.
Time frame: Cycle 3: Predose
Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, 0-24 Hours Postdose
Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.
Time frame: Cycle 3: 0-24 hours postdose
Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, 24-48 Hours Postdose
Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.
Time frame: Cycle 3: 24-48 hours postdose
Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, 48-72 Hours Postdose
Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.
Time frame: Cycle 3: 48-72 hours postdose
Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, 72-96 Hours Postdose
Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.
Time frame: Cycle 3: 72-96 hours postdose
Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, 96-120 Hours Postdose
Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.
Time frame: Cycle 3: 96-120 hours postdose
Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, 120-144 Hours Postdose
Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.
Time frame: Cycle 3: 120-144 hours postdose
Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, 144-168 Hours Postdose
Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.
Time frame: Cycle 3: 144-168 hours postdose
Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, 336-360 Hours Postdose
Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.
Time frame: Cycle 3: 336-360 hours postdose
Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, 480-504 Hours Postdose
Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.
Time frame: Cycle 3: 480-504 hours postdose
Serum Concentrations of Antibody-drug Conjugate (ADC)
The LLQ for all the observations was 12.5 ng/mL.
Time frame: Cycle 1 and 3: Predose, 0.5, 4, 72, 336 hours post-dose; Cycle 2: Predose, 0.5 hours post-dose; Cycle 3: 480 hours post-dose
Serum Concentration of Total Antibody (TAb)
The LLQ for all the observations was 12.5 ng/mL.
Time frame: Cycle 1 and 3: Predose, 0.5, 4, 72, 336 hours post-dose; Cycle 2: Predose, 0.5 hours post-dose; Cycle 3: 480 hours post-dose
Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; or congenital anomaly; or a medically important event. AEs included both SAE and non-SAE.
Time frame: Baseline up to 30 days after last dose of study drug (30 days after Cycle 16)
Number of Participants With Anti-therapeutic Antibodies (ATA) to Brentuximab Vedotin
Participants with positive ATA at both Cycle 1 and 3, negative ATA at both Cycle 1 and 3, and transient positive (positive at one time point, but negative at the other) ATA for brentuximab vedotin were reported.
Time frame: Day 1 of Cycle 1 and 3
Number of Participants With Markedly Abnormal Laboratory Values
The number of participants with any markedly abnormal standard safety laboratory values collected throughout study.
Time frame: Baseline up to 30 days after last dose of study drug (30 Days after Cycle 16)
Number of Participants With Clinically Significant Change From Baseline in Vital Signs
Vital signs included body temperature, body weight, blood pressure and heart rate.
Time frame: Baseline up to 30 days after last dose of study drug (30 Days after Cycle 16)
Participants took part in the study at 5 investigative sites in Belgium, Lithuania and Spain from 27 November 2013 to 16 June 2015.
| Milestone | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin |
|---|---|---|
| Started | 10 | 10 |
| Completed | 0 | 0 |
| Not completed | 10 | 10 |
| Withdrew: Adverse event | 3 | 0 |
| Withdrew: Stem cell transplant | 2 | 6 |
| Withdrew: Disease progression | 5 | 2 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Protocol violation | 0 | 1 |
Metabolites of MMAE includes C4, C5, C7, C8 and C13. The lower limit of Quantification (LLQ) for all the observations was 0.01 nanogram/milliliter (ng/mL).
| ng/mL | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin |
|---|---|---|
| MMAE | NA ± NA | NA ± NA |
| C4 | NA ± NA | NA ± NA |
| C5 | NA ± NA | NA ± NA |
| C7 | NA ± NA | NA ± NA |
| C8 | NA ± NA | NA ± NA |
| C13 | NA ± NA | NA ± NA |
The LLQ for all the observations was 12.5 ng/mL.
| ng/mL | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin |
|---|---|---|
| Cycle 1, Predose | NA ± NA | NA ± NA |
| Cycle 1, 0.5 hour | 29609.7759 ± 11865.35702 | 33125.0025 ± 10398.79403 |
| Cycle 1, 4 hour | 24398.6482 ± 8092.41448 | 24533.2372 ± 6767.70744 |
| Cycle 1, 72 hour | 4265.7542 ± 2880.39660 | 5958.0569 ± 1788.56378 |
| Cycle 1, 336 hour | 1167.0713 ± 740.05650 | 1108.6515 ± 376.81123 |
| Cycle 2, Predose | 794.3851 ± 10732.46886 | 435.1550 ± 303.25245 |
| Cycle 2, 0.5 hour | 16032.6494 ± 15714.59821 | 31627.2566 ± 6716.71906 |
| Cycle 3, Predose | 611.0573 ± 786.52082 | 536.3692 ± 524.72923 |
| Cycle 3, 0.5 hour | 20991.9618 ± 12662.05087 | 33040.2245 ± 6295.45517 |
| Cycle 3, 4 hour | 15378.8274 ± 9550.99903 | 24496.7203 ± 4212.84997 |
| Cycle 3, 72 hour | 3258.7237 ± 3358.78504 | 4262.0364 ± 2431.24647 |
| Cycle 3, 336 hour | 1381.2290 ± 1224.66857 | 1363.9488 ± 789.04877 |
| Cycle 3, 480 hour | 648.2492 ± 1065.26404 | 734.5557 ± 634.23889 |
The LLQ for all the observations was 12.5 ng/mL.
| ng/mL | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin |
|---|---|---|
| Cycle 1, Predose | NA ± NA | NA ± NA |
| Cycle 1, 0.5 hour | 30874.4957 ± 11904.18494 | 30884.9074 ± 9956.67036 |
| Cycle 1, 4 hour | 28577.3869 ± 9365.88746 | 28865.4674 ± 8192.50406 |
| Cycle 1, 72 hour | 9931.2943 ± 4973.74692 | 11626.2147 ± 4396.55604 |
| Cycle 1, 336 hour | 2898.2924 ± 1831.73997 | 3066.5859 ± 1017.84204 |
| Cycle 2, Predose | 2055.3871 ± 10312.91280 | 1363.8319 ± 904.27346 |
| Cycle 2, 0.5 hour | 17378.2105 ± 17543.51968 | 31583.7793 ± 7742.69918 |
| Cycle 3, Predose | 1361.3147 ± 1592.89993 | 1517.6506 ± 1200.68646 |
| Cycle 3, 0.5 hour | 15974.3723 ± 12467.10368 | 33892.4731 ± 10595.70675 |
| Cycle 3, 4 hour | 11609.1430 ± 14719.69968 | 27548.1773 ± 7219.71925 |
| Cycle 3, 72 hour | 13594.2016 ± 7492.70742 | 9588.9374 ± 5665.38218 |
| Cycle 3, 336 hour | 3206.6925 ± 3000.22116 | 3628.9175 ± 1802.66091 |
| Cycle 3, 480 hour | 1329.0886 ± 2024.17213 | 1866.5746 ± 1326.12113 |
Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.
| ng/mL | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin |
|---|---|---|
| MMAE | 0.0919 ± 0.05695 | 0.0795 ± 0.14220 |
| C4 | NA ± NA | NA ± NA |
| C5 | NA ± NA | NA ± NA |
| C7 | NA ± NA | NA ± NA |
| C8 | NA ± NA | NA ± NA |
| C13 | NA ± NA | NA ± NA |
Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.
| ng/mL | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin |
|---|---|---|
| MMAE | 0.1046 ± 0.10840 | 0.0727 ± 0.05936 |
| C4 | NA ± NA | NA ± NA |
| C5 | NA ± NA | NA ± NA |
| C7 | NA ± NA | NA ± NA |
| C8 | NA ± NA | NA ± NA |
| C13 | NA ± NA | NA ± NA |
Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.
| ng/mL | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin |
|---|---|---|
| MMAE | 0.3902 ± 1.33635 | 0.2149 ± 0.43900 |
| C4 | 0.0184 ± 0.00613 | NA ± NA |
| C5 | NA ± NA | NA ± NA |
| C7 | NA ± NA | NA ± NA |
| C8 | 0.0267 ± 0.02119 | NA ± NA |
| C13 | 0.0108 ± 0.00360 | NA ± NA |
Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.
| ng/mL | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin |
|---|---|---|
| MMAE | 0.3119 ± 1.69249 | 0.2929 ± 1.39185 |
| C4 | NA ± NA | NA ± NA |
| C5 | NA ± NA | NA ± NA |
| C7 | NA ± NA | NA ± NA |
| C8 | NA ± NA | 0.0228 ± 0.00760 |
| C13 | NA ± NA | NA ± NA |
Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.
| ng/mL | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin |
|---|---|---|
| MMAE | 0.3307 ± 2.33539 | 0.2577 ± 0.26736 |
| C4 | 0.0256 ± 0.00905 | NA ± NA |
| C5 | NA ± NA | NA ± NA |
| C7 | NA ± NA | NA ± NA |
| C8 | 0.0323 ± 0.03266 | NA ± NA |
| C13 | 0.0210 ± 0.00742 | NA ± NA |
Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.
| ng/mL | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin |
|---|---|---|
| MMAE | 2.2778 ± 4.42089 | 1.7836 ± 0.93129 |
| C4 | 0.0547 ± 0.02737 | NA ± NA |
| C5 | 0.0254 ± 0.01326 | NA ± NA |
| C7 | 0.0195 ± 0.01293 | NA ± NA |
| C8 | 0.0557 ± 0.05631 | 0.0160 ± 0.00921 |
| C13 | 0.0151 ± 0.00752 | NA ± NA |
Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.
| ng/mL | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin |
|---|---|---|
| MMAE | 1.7171 ± 4.42914 | 1.4529 ± 1.36620 |
| C4 | 0.0397 ± 0.01323 | NA ± NA |
| C5 | 0.0163 ± 0.00804 | NA ± NA |
| C7 | 0.0118 ± 0.00600 | NA ± NA |
| C8 | 0.0446 ± 0.05011 | 0.0190 ± 0.01265 |
| C13 | 0.0191 ± 0.00637 | NA ± NA |
Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.
| ng/mL | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin |
|---|---|---|
| MMAE | 3.7950 ± 4.12446 | 3.1227 ± 2.38909 |
| C4 | 0.0443 ± 0.05328 | 0.0191 ± 0.00637 |
| C5 | 0.0218 ± 0.02814 | NA ± NA |
| C7 | 0.0206 ± 0.01477 | NA ± NA |
| C8 | 0.0805 ± 0.06986 | 0.0196 ± 0.01702 |
| C13 | 0.0142 ± 0.00660 | 0.0113 ± 0.00377 |
Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.
| ng/mL | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin |
|---|---|---|
| MMAE | 3.2336 ± 2.26369 | 2.2558 ± 1.60345 |
| C4 | 0.0200 ± 0.01071 | NA ± NA |
| C5 | 0.0203 ± 0.01109 | NA ± NA |
| C7 | 0.0164 ± 0.00868 | NA ± NA |
| C8 | 0.0715 ± 0.04523 | 0.0177 ± 0.01284 |
| C13 | 0.0105 ± 0.00371 | NA ± NA |
Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.
| ng/mL | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin |
|---|---|---|
| MMAE | 4.2140 ± 3.69470 | 3.3727 ± 2.61792 |
| C4 | 0.0424 ± 0.05259 | 0.0128 ± 0.00565 |
| C5 | 0.0168 ± 0.02553 | NA ± NA |
| C7 | 0.0187 ± 0.01608 | NA ± NA |
| C8 | 0.0959 ± 0.06780 | 0.0210 ± 0.01455 |
| C13 | 0.0134 ± 0.00763 | NA ± NA |
Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.
| ng/mL | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin |
|---|---|---|
| MMAE | 3.4733 ± 2.17792 | 2.2156 ± 1.70890 |
| C4 | 0.0193 ± 0.01407 | NA ± NA |
| C5 | 0.0198 ± 0.01316 | NA ± NA |
| C7 | 0.0170 ± 0.01112 | NA ± NA |
| C8 | 0.0746 ± 0.06162 | 0.0195 ± 0.01114 |
| C13 | 0.0124 ± 0.00438 | NA ± NA |
Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.
| ng/mL | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin |
|---|---|---|
| MMAE | 3.8931 ± 3.61834 | 3.0948 ± 2.03516 |
| C4 | 0.0501 ± 0.06242 | 0.0127 ± 0.00423 |
| C5 | 0.0190 ± 0.02664 | NA ± NA |
| C7 | 0.0241 ± 0.01640 | NA ± NA |
| C8 | 0.0899 ± 0.06688 | 0.0187 ± 0.01111 |
| C13 | 0.0133 ± 0.00644 | NA ± NA |
Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.
| ng/mL | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin |
|---|---|---|
| MMAE | 3.3047 ± 2.14127 | 1.9732 ± 1.32391 |
| C4 | 0.0310 ± 0.01563 | NA ± NA |
| C5 | 0.0256 ± 0.01510 | NA ± NA |
| C7 | 0.0168 ± 0.01126 | NA ± NA |
| C8 | 0.0728 ± 0.04348 | 0.0187 ± 0.01079 |
| C13 | NA ± NA | NA ± NA |
Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.
| ng/mL | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin |
|---|---|---|
| MMAE | 2.9148 ± 1.70500 | 3.2956 ± 2.97022 |
| C4 | 0.0136 ± 0.00481 | 0.1420 ± 0.04733 |
| C5 | 0.0120 ± 0.00643 | 0.0593 ± 0.01977 |
| C7 | NA ± NA | 0.0374 ± 0.01247 |
| C8 | 0.0660 ± 0.04349 | 0.0228 ± 0.06198 |
| C13 | NA ± NA | 0.0108 ± 0.00360 |
Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.
| ng/mL | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin |
|---|---|---|
| MMAE | 2.4449 ± 1.44334 | 2.2344 ± 1.81211 |
| C4 | 0.0140 ± 0.00704 | 0.0418 ± 0.01393 |
| C5 | 0.0205 ± 0.01017 | 0.0294 ± 0.00980 |
| C7 | 0.0121 ± 0.00428 | 0.0252 ± 0.00840 |
| C8 | 0.0622 ± 0.04328 | 0.0392 ± 0.04163 |
| C13 | 0.0105 ± 0.00371 | NA ± NA |
Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.
| ng/mL | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin |
|---|---|---|
| MMAE | 2.3326 ± 1.45619 | 1.7990 ± 0.89695 |
| C4 | 0.0297 ± 0.02569 | NA ± NA |
| C5 | 0.0174 ± 0.01006 | NA ± NA |
| C7 | 0.0196 ± 0.00693 | NA ± NA |
| C8 | 0.0497 ± 0.02722 | 0.0120 ± 0.00542 |
| C13 | NA ± NA | NA ± NA |
Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.
| ng/mL | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin |
|---|---|---|
| MMAE | 2.0555 ± 1.07315 | 1.2920 ± 0.75690 |
| C4 | 0.0198 ± 0.00976 | NA ± NA |
| C5 | 0.0140 ± 0.00760 | NA ± NA |
| C7 | 0.0137 ± 0.00484 | NA ± NA |
| C8 | 0.0441 ± 0.02147 | 0.0145 ± 0.00648 |
| C13 | NA ± NA | NA ± NA |
Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.
| ng/mL | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin |
|---|---|---|
| MMAE | 0.3130 ± 0.15743 | 0.2723 ± 0.16544 |
| C4 | NA ± NA | NA ± NA |
| C5 | NA ± NA | NA ± NA |
| C7 | NA ± NA | NA ± NA |
| C8 | 0.0127 ± 0.00672 | NA ± NA |
| C13 | NA ± NA | NA ± NA |
Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.
| ng/mL | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin |
|---|---|---|
| MMAE | 0.4258 ± 0.30565 | 0.2578 ± 0.10847 |
| C4 | NA ± NA | NA ± NA |
| C5 | NA ± NA | NA ± NA |
| C7 | NA ± NA | NA ± NA |
| C8 | 0.0168 ± 0.01011 | NA ± NA |
| C13 | NA ± NA | NA ± NA |
Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.
| ng/mL | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin |
|---|---|---|
| MMAE | 0.1189 ± 0.15808 | 0.0941 ± 0.03974 |
| C4 | NA ± NA | NA ± NA |
| C5 | NA ± NA | NA ± NA |
| C7 | NA ± NA | NA ± NA |
| C8 | 0.0114 ± 0.00431 | NA ± NA |
| C13 | NA ± NA | NA ± NA |
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; or congenital anomaly; or a medically important event. AEs included both SAE and non-SAE.
| participants | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin |
|---|---|---|
| AEs | 9 | 9 |
| SAEs | 4 | 0 |
Participants with positive ATA at both Cycle 1 and 3, negative ATA at both Cycle 1 and 3, and transient positive (positive at one time point, but negative at the other) ATA for brentuximab vedotin were reported.
| participants | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin |
|---|---|---|
| Negative in both Cycle 1 and 3 | 5 | 7 |
| Positive in both Cycle 1 and 3 | 1 | 0 |
| Transient Positive | 2 | 2 |
The number of participants with any markedly abnormal standard safety laboratory values collected throughout study.
| participants | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin |
|---|---|---|
| Number of Participants With Markedly Abnormal Laboratory Values | 5 | 5 |
Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.
| ng | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin |
|---|---|---|
| MMAE | NA ± NA | 7.8900 ± 2.63000 |
| C4 | NA ± NA | NA ± NA |
| C5 | NA ± NA | NA ± NA |
| C7 | NA ± NA | NA ± NA |
| C8 | NA ± NA | 0.0712 ± 0.02373 |
| C13 | NA ± NA | NA ± NA |
Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.
| ng | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin |
|---|---|---|
| MMAE | 12.5668 ± 5.31374 | 12.5020 ± 6.85958 |
| C4 | 0.0878 ± 0.13223 | 0.0521 ± 0.02335 |
| C5 | 0.0883 ± 0.10135 | 0.0254 ± 0.00847 |
| C7 | NA ± NA | NA ± NA |
| C8 | 0.5967 ± 0.56221 | 0.1047 ± 0.07785 |
| C13 | 0.0786 ± 0.11460 | 0.0456 ± 0.03714 |
Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.
| ng | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin |
|---|---|---|
| MMAE | 12.6225 ± 6.93735 | 11.7995 ± 6.20286 |
| C4 | 0.0690 ± 0.10935 | 0.0392 ± 0.03010 |
| C5 | 0.0863 ± 0.09138 | 0.0277 ± 0.01700 |
| C7 | NA ± NA | NA ± NA |
| C8 | 0.7275 ± 0.59716 | 0.1568 ± 0.08381 |
| C13 | 0.0722 ± 0.07482 | 0.0405 ± 0.03473 |
Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.
| ng | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin |
|---|---|---|
| MMAE | 12.4089 ± 4.49922 | 11.6600 ± 5.45329 |
| C4 | 0.0812 ± 0.15006 | 0.0419 ± 0.02694 |
| C5 | 0.0867 ± 0.10841 | 0.0322 ± 0.01859 |
| C7 | NA ± NA | NA ± NA |
| C8 | 0.7973 ± 0.38226 | 0.1189 ± 0.08494 |
| C13 | 0.0786 ± 0.05672 | 0.0382 ± 0.02718 |
Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.
| ng | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin |
|---|---|---|
| MMAE | 10.7766 ± 8.14858 | 12.8426 ± 5.93538 |
| C4 | 0.0867 ± 0.16449 | 0.0427 ± 0.02848 |
| C5 | 0.0882 ± 0.11202 | 0.0394 ± 0.02131 |
| C7 | NA ± NA | NA ± NA |
| C8 | 0.7480 ± 0.61219 | 0.1247 ± 0.08379 |
| C13 | 0.0754 ± 0.06820 | 0.0415 ± 0.02723 |
Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.
| ng | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin |
|---|---|---|
| MMAE | 10.8018 ± 12.03431 | 9.5626 ± 7.26020 |
| C4 | 0.0885 ± 0.11811 | 0.0414 ± 0.03529 |
| C5 | 0.1053 ± 0.10639 | 0.0406 ± 0.02753 |
| C7 | NA ± NA | NA ± NA |
| C8 | 0.7360 ± 1.02417 | 0.1034 ± 0.10563 |
| C13 | 0.0630 ± 0.08155 | 0.0380 ± 0.03436 |
Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.
| ng | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin |
|---|---|---|
| MMAE | 6.7161 ± 6.13997 | 7.9830 ± 4.33309 |
| C4 | 0.0730 ± 0.08387 | 0.0335 ± 0.02037 |
| C5 | 0.0836 ± 0.07377 | 0.0301 ± 0.01767 |
| C7 | NA ± NA | NA ± NA |
| C8 | 0.4477 ± 0.56047 | 0.0910 ± 0.06044 |
| C13 | 0.0551 ± 0.05107 | 0.0345 ± 0.01738 |
Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.
| ng | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin |
|---|---|---|
| MMAE | 5.5693 ± 3.50945 | 5.8025 ± 3.45889 |
| C4 | 0.0579 ± 0.06807 | 0.0448 ± 0.02158 |
| C5 | 0.0747 ± 0.05078 | 0.0287 ± 0.01527 |
| C7 | NA ± NA | NA ± NA |
| C8 | 0.3916 ± 0.34491 | 0.0706 ± 0.03027 |
| C13 | 0.0438 ± 0.03146 | 0.0363 ± 0.01283 |
Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.
| ng | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin |
|---|---|---|
| MMAE | 1.0727 ± 0.55233 | 1.3326 ± 0.80959 |
| C4 | 0.0459 ± 0.01530 | NA ± NA |
| C5 | 0.0289 ± 0.00963 | NA ± NA |
| C7 | NA ± NA | NA ± NA |
| C8 | 0.0751 ± 0.04505 | 0.0401 ± 0.02242 |
| C13 | NA ± NA | NA ± NA |
Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.
| ng | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin |
|---|---|---|
| MMAE | 0.4420 ± 0.30745 | 0.3505 ± 0.14592 |
| C4 | NA ± NA | NA ± NA |
| C5 | NA ± NA | NA ± NA |
| C7 | NA ± NA | NA ± NA |
| C8 | 0.0578 ± 0.03314 | NA ± NA |
| C13 | NA ± NA | NA ± NA |
Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.
| ng | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin |
|---|---|---|
| MMAE | 0.3171 ± 0.33548 | 0.4227 ± 0.17918 |
| C4 | NA ± NA | NA ± NA |
| C5 | NA ± NA | NA ± NA |
| C7 | NA ± NA | NA ± NA |
| C8 | 0.0392 ± 0.02985 | NA ± NA |
| C13 | NA ± NA | NA ± NA |
Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.
| ng | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin |
|---|---|---|
| MMAE | 10.7174 ± 15.35912 | 12.4438 ± 8.86144 |
| C4 | 0.0454 ± 0.07644 | 0.0451 ± 0.02977 |
| C5 | 0.0509 ± 0.04623 | 0.0301 ± 0.01847 |
| C7 | NA ± NA | NA ± NA |
| C8 | 0.4657 ± 0.41352 | 0.1285 ± 0.17930 |
| C13 | 0.0516 ± 0.07045 | 0.0676 ± 0.05022 |
Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.
| ng | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin |
|---|---|---|
| MMAE | 11.1360 ± 6.73693 | 13.2483 ± 4.79482 |
| C4 | 0.0604 ± 0.05049 | 0.0413 ± 0.03095 |
| C5 | 0.0808 ± 0.06838 | 0.0311 ± 0.02021 |
| C7 | NA ± NA | NA ± NA |
| C8 | 0.5750 ± 0.58196 | 0.1600 ± 0.11946 |
| C13 | 0.0637 ± 0.05102 | 0.0507 ± 0.03607 |
Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.
| ng | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin |
|---|---|---|
| MMAE | 12.7267 ± 8.96991 | 13.8072 ± 8.63973 |
| C4 | 0.0620 ± 0.06222 | 0.0524 ± 0.04691 |
| C5 | 0.0746 ± 0.09237 | 0.0406 ± 0.03034 |
| C7 | NA ± NA | NA ± NA |
| C8 | 0.6950 ± 0.83588 | 0.1598 ± 0.14846 |
| C13 | 0.0632 ± 0.06480 | 0.0746 ± 0.05134 |
Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.
| ng | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin |
|---|---|---|
| MMAE | 11.2527 ± 8.65574 | 12.2263 ± 6.09003 |
| C4 | 0.0702 ± 0.07079 | 0.0611 ± 0.05055 |
| C5 | 0.0937 ± 0.10757 | 0.0437 ± 0.03084 |
| C7 | NA ± NA | NA ± NA |
| C8 | 0.5276 ± 0.95507 | 0.1510 ± 0.11532 |
| C13 | 0.0573 ± 0.07734 | 0.0564 ± 0.03759 |
Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.
| ng | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin |
|---|---|---|
| MMAE | 8.3817 ± 7.78279 | 8.1426 ± 7.29530 |
| C4 | 0.0710 ± 0.05912 | 0.0512 ± 0.04137 |
| C5 | 0.0916 ± 0.08893 | 0.0435 ± 0.02885 |
| C7 | NA ± NA | NA ± NA |
| C8 | 0.5198 ± 0.79634 | 0.1088 ± 0.09569 |
| C13 | 0.0607 ± 0.06838 | 0.0524 ± 0.03619 |
Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.
| ng | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin |
|---|---|---|
| MMAE | 7.3500 ± 3.78427 | 7.5871 ± 4.66863 |
| C4 | 0.0461 ± 0.03666 | 0.0520 ± 0.03870 |
| C5 | 0.0657 ± 0.04811 | 0.0342 ± 0.02508 |
| C7 | NA ± NA | NA ± NA |
| C8 | 0.4700 ± 0.37131 | 0.0869 ± 0.07672 |
| C13 | 0.0386 ± 0.03212 | 0.0429 ± 0.02820 |
Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.
| ng | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin |
|---|---|---|
| MMAE | 6.1125 ± 3.83207 | 4.6823 ± 2.80767 |
| C4 | 0.0538 ± 0.04252 | 0.0562 ± 0.02674 |
| C5 | 0.0662 ± 0.06110 | 0.0308 ± 0.01718 |
| C7 | NA ± NA | NA ± NA |
| C8 | 0.3485 ± 0.45898 | 0.0651 ± 0.03984 |
| C13 | 0.0402 ± 0.04117 | 0.0481 ± 0.01603 |
Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.
| ng | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin |
|---|---|---|
| MMAE | 1.2811 ± 1.55068 | 0.8271 ± 0.43597 |
| C4 | 0.0377 ± 0.01812 | NA ± NA |
| C5 | 0.0347 ± 0.02457 | NA ± NA |
| C7 | NA ± NA | NA ± NA |
| C8 | 0.0734 ± 0.10958 | 0.0277 ± 0.01306 |
| C13 | 0.0227 ± 0.00757 | NA ± NA |
Vital signs included body temperature, body weight, blood pressure and heart rate.
| participants | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin |
|---|---|---|
| Number of Participants With Clinically Significant Change From Baseline in Vital Signs | 1 | 2 |
Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.
| ng | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin |
|---|---|---|
| MMAE | 0.4660 ± 0.41713 | 0.3334 ± 0.25074 |
| C4 | 0.0248 ± 0.00827 | NA ± NA |
| C5 | 0.0377 ± 0.01257 | NA ± NA |
| C7 | NA ± NA | NA ± NA |
| C8 | 0.0620 ± 0.04967 | 0.0221 ± 0.00737 |
| C13 | NA ± NA | NA ± NA |
Collected over Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days after the last dose of study drug (30 days after Cycle 16).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brentuximab Vedotin | — | 4/10 (40%) | 9/10 (90%) |
| Brentuximab Vedotin + Rifampicin | — | 0/10 (0%) | 9/10 (90%) |
| Event | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin |
|---|---|---|
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 2/10 | 0/10 |
| Thrombosis in deviceGeneral disorders | 1/10 | 0/10 |
| PyrexiaGeneral disorders | 1/10 | 0/10 |
| Staphylococcal infectionInfections and infestations | 1/10 | 0/10 |
| Pulmonary tuberculosisInfections and infestations | 1/10 | 0/10 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/10 | 0/10 |
| Pneumocystis jirovecii pneumoniaInfections and infestations | 1/10 | 0/10 |
| NeuralgiaNervous system disorders | 1/10 | 0/10 |
| Event | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin |
|---|---|---|
| PruritusSkin and subcutaneous tissue disorders | 3/10 | 3/10 |
| NeutropeniaBlood and lymphatic system disorders | 3/10 | 2/10 |
| AnaemiaBlood and lymphatic system disorders | 2/10 | 2/10 |
| DiarrhoeaGastrointestinal disorders | 1/10 | 2/10 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/10 | 2/10 |
| EosinophiliaBlood and lymphatic system disorders | 1/10 | 2/10 |
| HypokalaemiaMetabolism and nutrition disorders | 2/10 | 1/10 |
| HypomagnesaemiaMetabolism and nutrition disorders | 2/10 | 1/10 |
| Peripheral sensory neuropathyNervous system disorders | 1/10 | 2/10 |
| PyrexiaGeneral disorders | 1/10 | 2/10 |
Safety population included all participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin | Total |
|---|---|---|---|
| Mean | 42.3 ± 12.15 | 40.1 ± 9.13 | 41.2 ± 10.52 |
| Sex: Female, Male(Participants) | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin | Total |
|---|---|---|---|
| Female | 3 | 6 | 9 |
| Male | 7 | 4 | 11 |
| Race/Ethnicity, Customized(participants) | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin | Total |
|---|---|---|---|
| White | 10 | 10 | 20 |
| Race/Ethnicity, Customized(participants) | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin | Total |
|---|---|---|---|
| Not Hispanic or Latino | 10 | 10 | 20 |
| Region of Enrollment(participants) | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin | Total |
|---|---|---|---|
| Spain | 4 | 5 | 9 |
| Belgium | 2 | 1 | 3 |
| Lithuania | 4 | 4 | 8 |
| Weight(kilogram (kg)) | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin | Total |
|---|---|---|---|
| Mean | 71.11 ± 17.056 | 76.84 ± 24.213 | 73.98 ± 20.595 |
| Height(centimeter (cm)) | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin | Total |
|---|---|---|---|
| Mean | 169.9 ± 3.80 | 169.7 ± 6.45 | 169.8 ± 5.15 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(participants) | Brentuximab Vedotin | Brentuximab Vedotin + Rifampicin | Total |
|---|---|---|---|
| 0 | 3 | 6 | 9 |
| 1 | 6 | 4 | 10 |
| 2 | 1 | 0 | 1 |
3 further baseline measures are reported on the registry.
The record gives a start of Nov 2013, a primary completion of Oct 2014 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2016, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Brentuximab Vedotin · Rifampin
Millennium Pharmaceuticals, Inc. →